Prognostic Factors in Curative Resected Locoregional Small Intestine Neuroendocrine Neoplasms.
Journal
World journal of surgery
ISSN: 1432-2323
Titre abrégé: World J Surg
Pays: United States
ID NLM: 7704052
Informations de publication
Date de publication:
Apr 2021
Apr 2021
Historique:
accepted:
14
11
2020
pubmed:
9
1
2021
medline:
25
6
2021
entrez:
8
1
2021
Statut:
ppublish
Résumé
Small intestinal neuroendocrine neoplasms (SI-NEN) are rare, and only about 40% of patients are diagnosed without distant metastases. Aim of the study was to identify prognostic factors in patients with potentially curative resected locoregional SI-NEN. Patients with curative resected locoregional SI-NEN (ENETS stages I-III) were retrieved from a prospective data base. Demographic, surgical and pathological data of patients with and without disease recurrence were retrospectively analyzed using univariate and multivariate analysis. In a 20-year period, 65 of 203 (32%) patients with SI-NEN were operated for stages I-III disease. Thirty-eight (58.5%) patients were men, and the median age at surgery was 59 (range 37-87) years. After median follow-up of 65 months, 14 patients experienced disease relapse median 28.5 (range 6-122) months after initial surgery, of which 2 died due to their disease. Multivariate analysis revealed age ≥ 60 years (HR = 6.41, 95% CI 1.38-29.67, p = 0.017), tumor size ≥ 2 cm (HR = 26.54, 95% CI 4.46-157.62, p < 0.001), lymph node ratio > 0.5 (HR 7.18, 95% CI 1.74-29.74, p = 0.007) and multifocal tumor growth (HR = 6.98, 95% CI 1.66-29.39, p = 0.008) as independent negative prognostic factors and right hemicolectomy compared to segmental small bowel resection (HR = 0.04, 95% CI 0.01-0.24, p < 0.001) as independent protector against recurrence. Patients with locoregional SI-NEN with an age ≥ 60 years, tumor size ≥ 2 cm, lymph node ratio > 0.5 and multiple small bowel tumor foci have an increased risk for recurrence and might benefit from adjuvant treatment. In contrast, right hemicolectomy of ileal SI-NEN seems to reduce the risk of recurrence.
Sections du résumé
BACKGROUND
BACKGROUND
Small intestinal neuroendocrine neoplasms (SI-NEN) are rare, and only about 40% of patients are diagnosed without distant metastases. Aim of the study was to identify prognostic factors in patients with potentially curative resected locoregional SI-NEN.
METHODS
METHODS
Patients with curative resected locoregional SI-NEN (ENETS stages I-III) were retrieved from a prospective data base. Demographic, surgical and pathological data of patients with and without disease recurrence were retrospectively analyzed using univariate and multivariate analysis.
RESULTS
RESULTS
In a 20-year period, 65 of 203 (32%) patients with SI-NEN were operated for stages I-III disease. Thirty-eight (58.5%) patients were men, and the median age at surgery was 59 (range 37-87) years. After median follow-up of 65 months, 14 patients experienced disease relapse median 28.5 (range 6-122) months after initial surgery, of which 2 died due to their disease. Multivariate analysis revealed age ≥ 60 years (HR = 6.41, 95% CI 1.38-29.67, p = 0.017), tumor size ≥ 2 cm (HR = 26.54, 95% CI 4.46-157.62, p < 0.001), lymph node ratio > 0.5 (HR 7.18, 95% CI 1.74-29.74, p = 0.007) and multifocal tumor growth (HR = 6.98, 95% CI 1.66-29.39, p = 0.008) as independent negative prognostic factors and right hemicolectomy compared to segmental small bowel resection (HR = 0.04, 95% CI 0.01-0.24, p < 0.001) as independent protector against recurrence.
CONCLUSION
CONCLUSIONS
Patients with locoregional SI-NEN with an age ≥ 60 years, tumor size ≥ 2 cm, lymph node ratio > 0.5 and multiple small bowel tumor foci have an increased risk for recurrence and might benefit from adjuvant treatment. In contrast, right hemicolectomy of ileal SI-NEN seems to reduce the risk of recurrence.
Identifiants
pubmed: 33416940
doi: 10.1007/s00268-020-05884-6
pii: 10.1007/s00268-020-05884-6
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1109-1117Références
Niederle B, Pape UF, Costa F et al (2016) ENETS consensus guidelines update for neuroendocrine neoplasms of the jejunum and ileum. Neuroendocrinology 103:125–138
doi: 10.1159/000443170
Eriksson J, Norlén O, Ögren M et al (2019) Primary small intestinal neuroendocrine tumors are highly prevalent and often multiple before metastatic disease develops. Scand J Surg. https://doi.org/10.1177/1457496919874484
doi: 10.1177/1457496919874484
pubmed: 31587594
Walsh JC, Schaeffer DF, Kirsch R et al (2016) Ileal “carcinoid” tumors-small size belies deadly intent: high rate of nodal metastasis in tumors ≤1 cm in size. Hum Pathol 56:123–127
doi: 10.1016/j.humpath.2016.05.023
Watzka FM, Fottner C, Miederer M et al (2016) Surgical treatment of NEN of small bowel: a retrospective analysis. World J Surg 40:749–758. https://doi.org/10.1007/s00268-016-3432-2
doi: 10.1007/s00268-016-3432-2
pubmed: 26822157
Ter-Minassian M, Chan JA, Hooshmand SM et al (2013) Clinical presentation, recurrence, and survival in patients with neuroendocrine tumors: results from a prospective institutional database. Endocr Relat Cancer 20(2):187–196
doi: 10.1530/ERC-12-0340
Ohrvall U, Eriksson B, Juhlin C et al (2000) Method for dissection of mesenteric metastases in mid-gut carcinoid tumors. World J Surg 24(11):1402–1408. https://doi.org/10.1007/s002680010232
doi: 10.1007/s002680010232
pubmed: 11038214
Akerström G, Hellman P, Hessman O et al (2005) Management of midgut carcinoids. J Surg Oncol 89(3):161–169
doi: 10.1002/jso.20188
Partelli S, Bartsch DK, Capdevila J et al (2017) ENETS consensus guidelines for standard of care in neuroendocrine tumours: surgery for small intestinal and pancreatic neuroendocrine tumours. Neuroendocrinology 105(3):255–265
doi: 10.1159/000464292
Yao JC, Hassan M, Phan A et al (2008) One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 26:3063–3072
doi: 10.1200/JCO.2007.15.4377
Dasari A, Shen C, Halperin D et al (2017) Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol 3(10):1335–1342
doi: 10.1001/jamaoncol.2017.0589
Boudreaux JP, Klimstra DS, Hassan MM et al (2010) The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the Jejunum, Ileum, Appendix, and Cecum. Pancreas 39(6):753–766
doi: 10.1097/MPA.0b013e3181ebb2a5
Jann H, Roll S, Couvelard A et al (2011) Neuroendocrine tumors of midgut and hindgut origin: tumor-node-metastasis classification determines clinical outcome. Cancer 117:3332–3341
doi: 10.1002/cncr.25855
Zaidi MY, Lopez-Aguiar AG, Dillhoff M et al (2019) Prognostic role of lymph node positivity and number of lymph nodes needed for accurately staging small-bowel neuroendocrine tumors. JAMA Surg 154(2):134–140
doi: 10.1001/jamasurg.2018.3865
Le Roux C, Lombard-Bohas C, Delmas C et al (2011) Relapse factors for ileal neuroendocrine tumours after curative surgery: a retrospective French multicentre study. Dig Liver Dis 43(10):828–833
doi: 10.1016/j.dld.2011.04.021
Cives M, Anaya DA, Soares H et al (2018) Analysis of postoperative recurrence in stage I-III midgut neuroendocrine tumors. J Natl Cancer Inst 110(3):282–289
doi: 10.1093/jnci/djx174
Slagter AE, Ryder D, Chakrabarty B et al (2016) Prognostic factors for disease relapse in patients with neuroendocrine tumours who underwent curative surgery. Surg Oncol 25(3):223–228
doi: 10.1016/j.suronc.2016.05.019
Kim S, Marcus R, Wells ML et al (2020) The evolving role of imaging for small bowel neuroendocrine neoplasms: estimated impact of imaging and disease-free survival in a retrospective observational study. Abdom Radiol 45(3):623–631
doi: 10.1007/s00261-020-02410-z
Rindi G, Klöppel G, Couvelard A et al (2007) TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch 451(4):757–762
doi: 10.1007/s00428-007-0452-1
Brierley JD, Gospodarowicz MK, Wittekind C (2017) Well-differentiated neuroendocrine tumours of the gastrointestinal tract. The TNM classification of malignant tumours, 8th edn. Wiley Blackwell, Oxford, pp 96–104
Dindo D, Demartines N, Clavien PA (2004) Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 240(2):205–213
doi: 10.1097/01.sla.0000133083.54934.ae
Knigge U, Capdevila J, Bartsch DK et al (2009) ENETS consensus recommendations for the standards of care in neuroendocrine tumors: follow-up and documentation. Neuroendocrinology 105(3):310–319
doi: 10.1159/000458155
Dieckhoff P, Runkel H, Daniel H et al (2014) Well-differentiated neuroendocrine neoplasia: relapse-free survival and predictors of recurrence after curative intended resections. Digestion 90(2):89–97
doi: 10.1159/000365143
Habbe N, Fendrich V, Heverhagen A et al (2013) Outcome of surgery for ileojejunal neuroendocrine tumors. Surg Today 43(10):1168–1174
doi: 10.1007/s00595-012-0408-1
Norlén O, Stålberg P, Öberg K et al (2012) Long-term results of surgery for small intestinal neuroendocrine tumors at a tertiary referral center. World J Surg 36(6):1419–1431. https://doi.org/10.1007/s00268-011-1296-z
doi: 10.1007/s00268-011-1296-z
pubmed: 21984144
Wu L, Fu J, Wan L et al (2017) Survival outcomes and surgical intervention of small intestinal neuroendocrine tumors: a population based retrospective study. Oncotarget 8(3):4935–4947
doi: 10.18632/oncotarget.13632
Zar N, Garmo H, Holmberg L et al (2004) Long-term survival of patients with small intestinal carcinoid tumors. World J Surg 28(11):1163–1168. https://doi.org/10.1007/s00268-004-7610-2
doi: 10.1007/s00268-004-7610-2
pubmed: 15490058
Ahmed A, Turner G, King B et al (2009) Midgut neuroendocrine tumours with liver metastases: results of the UKINETS study. Endocr Relat Cancer 16(3):885–894
doi: 10.1677/ERC-09-0042
Yantiss RK, Odze RD, Farraye FA et al (2003) Solitary versus multiple carcinoid tumors of the ileum: a clinical and pathologic review of 68 cases. Am J Surg 27(6):811–817
Merath K, Bagante F, Beal EW et al (2018) Nomogram predicting the risk of recurrence after curative-intent resection of primary non-metastatic gastrointestinal neuroendocrine tumors: an analysis of the U.S. neuroendocrine tumor study group. J Surg Oncol 117(5):868–878
doi: 10.1002/jso.24985
Strosberg J, Nasir A, Coppola D et al (2009) Correlation between grade and prognosis in metastatic gastroenteropancreatic neuroendocrine tumors. Hum Pathol 40(9):1262–1268
doi: 10.1016/j.humpath.2009.01.010
Landry CS, Lin HY, Phan A et al (2013) Resection of at-risk mesenteric lymph nodes is associated with improved survival in patients with small bowel neuroendocrine tumors. World J Surg 37:1695–1700. https://doi.org/10.1007/s00268-013-1918-8
doi: 10.1007/s00268-013-1918-8
pubmed: 23657749
Kim MK, Warner RR, Ward SC et al (2015) Prognostic significance of lymph node metastases in small intestinal neuroendocrine tumors. Neuroendocrinology 101(1):58–65
doi: 10.1159/000371807
Manguso N, Johnson J, Hari A, Nisse N, Mirocha J, Hendifar A, Amersi F (2017) Prognostic factors associated with outcomes in small bowel neuroendocrine tumors. Am Surg 83(10):1174–1178
doi: 10.1177/000313481708301033